Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2022

Open Access 01-12-2022 | Hypophosphatemic Rickets | Case report

Tumor-induced osteomalacia: a case report

Authors: Khalid Aligail, Joel A. Dave, Ian Louis Ross

Published in: Journal of Medical Case Reports | Issue 1/2022

Login to get access

Abstract

Background

Tumor-induced osteomalacia is a rare, acquired paraneoplastic syndrome, including hypophosphatemia, high serum alkaline phosphatase, reduced active vitamin D, suboptimal bone mineral density, bone pain, fragility fractures, and muscle weakness.

Case presentation

We report a case of 74–year–old male of mixed ancestry with hypophosphatemia resistant to treatment despite optimal compliance, associated with profound reduction of bone mineral density and multiple nontraumatic fractures, including bilateral rib fractures, lower-thoracic (T11, T12) vertebrae, and two fractures involving the surgical and anatomical neck of the right humerus. We discuss an approach to identifying the underlying cause of hypophosphatemia associated with fragility fractures, and options for management of this rare condition.

Conclusion

Although rare, tumor-induced osteomalacia can be diagnosed if a logical stepwise approach is implemented. Surgery could be curative if the tumor is properly located and is resectable.
Literature
1.
go back to reference Minisola S, et al. Tumour-induced osteomalacia. Nat Rev Dis Primers. 2017;3(1):1–15.CrossRef Minisola S, et al. Tumour-induced osteomalacia. Nat Rev Dis Primers. 2017;3(1):1–15.CrossRef
2.
go back to reference Lewiecki EM, Urig EJ Jr, Williams RC Jr. Tumor-induced osteomalacia: lessons learned. Arthrit Rheum. 2008;58(3):773–7.CrossRef Lewiecki EM, Urig EJ Jr, Williams RC Jr. Tumor-induced osteomalacia: lessons learned. Arthrit Rheum. 2008;58(3):773–7.CrossRef
3.
go back to reference Reginato AJ, Coquia JA. Musculoskeletal manifestations of osteomalacia and rickets. Best Pract Res Clin Rheumatol. 2003;17(6):1063–80.CrossRef Reginato AJ, Coquia JA. Musculoskeletal manifestations of osteomalacia and rickets. Best Pract Res Clin Rheumatol. 2003;17(6):1063–80.CrossRef
4.
go back to reference Hazzazi MA, et al. Clinical presentation and etiology of osteomalacia/rickets in adolescents. Saudi J Kidney Dis Transplant. 2013;24(5):938.CrossRef Hazzazi MA, et al. Clinical presentation and etiology of osteomalacia/rickets in adolescents. Saudi J Kidney Dis Transplant. 2013;24(5):938.CrossRef
5.
go back to reference Penido MGM, Alon US. Phosphate homeostasis and its role in bone health. Pediatr Nephrol. 2012;27(11):2039–48.CrossRef Penido MGM, Alon US. Phosphate homeostasis and its role in bone health. Pediatr Nephrol. 2012;27(11):2039–48.CrossRef
6.
go back to reference Thalayasingam B. Coeliac disease as a cause of osteomalacia and rickets in the Asian immigrant population. Br Med J (Clin Res Ed). 1985;290(6475):1146.CrossRef Thalayasingam B. Coeliac disease as a cause of osteomalacia and rickets in the Asian immigrant population. Br Med J (Clin Res Ed). 1985;290(6475):1146.CrossRef
7.
go back to reference Hughes MR, et al. Regulation of serum 1alpha, 25-dihydroxyvitamin D3 by calcium and phosphate in the rat. Science. 1975;190(4214):578–80.CrossRef Hughes MR, et al. Regulation of serum 1alpha, 25-dihydroxyvitamin D3 by calcium and phosphate in the rat. Science. 1975;190(4214):578–80.CrossRef
8.
go back to reference Hutchison FN, Bell NH. Osteomalacia and rickets. In: Seminars in nephrology; Amsterdam: Elsevier. 1992. Hutchison FN, Bell NH. Osteomalacia and rickets. In: Seminars in nephrology; Amsterdam: Elsevier. 1992.
10.
go back to reference Peacock M, et al. The action of 1αhydroxy vitamin D 3 and phosphate supplements in hypophosphataemic osteomalacia. In: Phosphate metabolism. Springer; 1977. p. 431–40.CrossRef Peacock M, et al. The action of 1αhydroxy vitamin D 3 and phosphate supplements in hypophosphataemic osteomalacia. In: Phosphate metabolism. Springer; 1977. p. 431–40.CrossRef
11.
go back to reference Yin Z, et al. Tumor-induced osteomalacia. Osteoporos Sarcopenia. 2018;4(4):119–27.CrossRef Yin Z, et al. Tumor-induced osteomalacia. Osteoporos Sarcopenia. 2018;4(4):119–27.CrossRef
12.
go back to reference Cundy T, et al. Bisphosphonate-induced deterioration of osteomalacia in undiagnosed adult Fanconi syndrome. JBMR Plus. 2020;4(8):e10374.CrossRef Cundy T, et al. Bisphosphonate-induced deterioration of osteomalacia in undiagnosed adult Fanconi syndrome. JBMR Plus. 2020;4(8):e10374.CrossRef
13.
go back to reference Jung G-H, et al. A 9-month-old phosphaturic mesenchymal tumor mimicking the intractable rickets. J Pediatric Orthop B. 2010;19(1):127–32.CrossRef Jung G-H, et al. A 9-month-old phosphaturic mesenchymal tumor mimicking the intractable rickets. J Pediatric Orthop B. 2010;19(1):127–32.CrossRef
14.
go back to reference Feng J, et al. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocrine J. 2017; EJ16-0587. Feng J, et al. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocrine J. 2017; EJ16-0587.
15.
go back to reference White KE, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001;86(2):497–500.CrossRef White KE, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001;86(2):497–500.CrossRef
16.
go back to reference Pal R, et al. Tumor-induced osteomalacia: experience from three tertiary care centers in India. Endocr Connect. 2019;8(3):266–76.CrossRef Pal R, et al. Tumor-induced osteomalacia: experience from three tertiary care centers in India. Endocr Connect. 2019;8(3):266–76.CrossRef
17.
go back to reference Beygi S, Denio A, Sharma TS. The foot that broke both hips: a case report and literature review of tumor-induced osteomalacia. Case Rep Rheumatol. 2017;2017:1. Beygi S, Denio A, Sharma TS. The foot that broke both hips: a case report and literature review of tumor-induced osteomalacia. Case Rep Rheumatol. 2017;2017:1.
18.
go back to reference White KE, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26(3):345–8.CrossRef White KE, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26(3):345–8.CrossRef
19.
go back to reference Bergwitz C, Miyamoto K-I. Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy. Pflügers Archiv-Eur J Physiol. 2019;471(1):149–63.CrossRef Bergwitz C, Miyamoto K-I. Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy. Pflügers Archiv-Eur J Physiol. 2019;471(1):149–63.CrossRef
20.
go back to reference Sommer S, et al. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol. 2007;103(3–5):497–503.CrossRef Sommer S, et al. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol. 2007;103(3–5):497–503.CrossRef
21.
go back to reference González-Lamuño, D., Hypophosphataemic rickets: diagnosis algorithm—how not to make a mistake. Adv Therapy. 2020; 1–10. González-Lamuño, D., Hypophosphataemic rickets: diagnosis algorithm—how not to make a mistake. Adv Therapy. 2020; 1–10.
22.
go back to reference Urakawa I, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770–4.CrossRef Urakawa I, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770–4.CrossRef
23.
go back to reference Shimada T, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429–35.CrossRef Shimada T, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429–35.CrossRef
24.
go back to reference Sabbagh Y, et al. Intestinal phosphate transport. Adv Chronic Kidney Dis. 2011;18(2):85–90.CrossRef Sabbagh Y, et al. Intestinal phosphate transport. Adv Chronic Kidney Dis. 2011;18(2):85–90.CrossRef
25.
go back to reference Yamazaki Y, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002;87(11):4957–60.CrossRef Yamazaki Y, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002;87(11):4957–60.CrossRef
26.
go back to reference Reubi JC, et al. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Can Res. 1996;56(8):1922–31. Reubi JC, et al. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Can Res. 1996;56(8):1922–31.
27.
go back to reference El-Maouche D, et al. 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2016;101(10):3575–81.CrossRef El-Maouche D, et al. 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2016;101(10):3575–81.CrossRef
28.
go back to reference van Boekel G, et al. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur J Endocrinol. 2008;158(3):431–8.CrossRef van Boekel G, et al. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur J Endocrinol. 2008;158(3):431–8.CrossRef
29.
go back to reference Seufert J, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med. 2001;345(26):1883–8.CrossRef Seufert J, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med. 2001;345(26):1883–8.CrossRef
30.
go back to reference Kim DH, Sung DH, Min YK. Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. J Bone Miner Metab. 2013;31(2):240–6.CrossRef Kim DH, Sung DH, Min YK. Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. J Bone Miner Metab. 2013;31(2):240–6.CrossRef
31.
go back to reference Ovejero D, et al. Octreotide is ineffective in treating tumor-induced osteomalacia: results of a short-term therapy. J Bone Miner Res. 2017;32(8):1667–71.CrossRef Ovejero D, et al. Octreotide is ineffective in treating tumor-induced osteomalacia: results of a short-term therapy. J Bone Miner Res. 2017;32(8):1667–71.CrossRef
32.
go back to reference Ishii A, et al. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels. Calcif Tissue Int. 2010;86(6):455–62.CrossRef Ishii A, et al. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels. Calcif Tissue Int. 2010;86(6):455–62.CrossRef
33.
go back to reference Fukumoto S. FGF23-FGF receptor/Klotho pathway as a new drug target for disorders of bone and mineral metabolism. Calcif Tissue Int. 2016;98(4):334–40.CrossRef Fukumoto S. FGF23-FGF receptor/Klotho pathway as a new drug target for disorders of bone and mineral metabolism. Calcif Tissue Int. 2016;98(4):334–40.CrossRef
Metadata
Title
Tumor-induced osteomalacia: a case report
Authors
Khalid Aligail
Joel A. Dave
Ian Louis Ross
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2022
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-021-03220-7

Other articles of this Issue 1/2022

Journal of Medical Case Reports 1/2022 Go to the issue